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https://doi.org/10.1016/j.celrep.2020.107587SUMMARYHost genetic factors play a fundamental role in regulating humoral immunity to viral infection, including influ-
enza A virus (IAV). Here, we utilize the Collaborative Cross (CC), a mouse genetic reference population, to
study genetic regulation of variation in antibody response following IAV infection. CC mice show significant
heritable variation in themagnitude, kinetics, and composition of IAV-specific antibody response.Wemap 23
genetic loci associated with this variation. Analysis of a subset of these loci finds that they broadly affect the
antibody response to IAV as well as other viruses. Candidate genes are identified based on predicted variant
consequences and haplotype-specific expression patterns, and several showoverlapwith genes identified in
human mapping studies. These findings demonstrate that the host antibody response to IAV infection is un-
der complex genetic control and highlight the utility of the CC inmodeling and identifying genetic factors with
translational relevance to human health and disease.INTRODUCTION
The humoral immune response protects against pathogens
through mechanisms such as antibody-mediated neutralization,
opsonization, antibody-dependent cellular cytotoxicity, and initi-
ation of the classical complement pathway (Forthal, 2014). The
quality and/or magnitude of the antibody response is an impor-
tant correlate of protection against many pathogens, including
viruses such as influenza A virus (IAV) and severe acute respira-
tory syndrome coronavirus (SARS-CoV) (Couch et al., 2013;
Subbarao et al., 2004). IAV is a particularly large public health
burden, with seasonal IAV strains incurring significant morbidity
and mortality annually (estimated 50 million cases, 1 million hos-This is an open access article under the CC BY-Npitalizations, and 80 thousand deaths in the 2017-2018 season)
(Centers for Disease Control and Prevention, 2018). Though
vaccination is an important component of influenza control, ex-
isting influenza vaccines often exhibit low efficacy. While this is
partially due to antigenic mismatch between vaccines and circu-
lating influenza strains (Lewnard and Cobey, 2018), numerous
studies have shown that some individuals fail to mount a suffi-
cient protective antibody response upon vaccination (Wieder-
mann et al., 2016).
Multiple factors contribute to variation in an individual’s ability
to mount protective antigen-specific antibody responses
following infection or vaccination. These factors include age, un-
derlying disease states, and prior exposure history to relatedCell Reports 31, 107587, April 28, 2020 ª 2020 The Author(s). 1
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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some dissent (Brodin et al., 2015), multiple studies across
different pathogens and vaccines indicate that antibody
responses have a strong heritable component, with many esti-
mates of 50% (Kruskall et al., 1992; Linnik and Egli, 2016; Ov-
syannikova et al., 2012). In the case of the measles vaccine, the
antibody response was nearly 90% heritable, suggesting that
genetics are a predominant factor contributing to interindividual
variation in vaccine response (Tan et al., 2001). Despite this
strong evidence for the role of genetic variation in modulating
antibody response, the genetic factors regulating antibody
response to IAV are unknown. Complicating this type of analysis
is the fact that antibody response is the downstream result of a
complex immunological process involving multiple tissues, cell
types, and cell signaling pathways. Genes underlying variation
in antibody response may be involved in any stage of the
response, from general regulatory aspects of B cell development
to more IAV-specific effects such as innate immune sensing. An
understanding of naturally polymorphic genes involved in the
antibody response, how they function, and whether their effects
are broad or pathogen specific could lead to improved vaccine
design, such as by utilization of adjuvants that specifically target
relevant pathways and boost antibody response.
Despite the importance of understanding genetic regulation of
pathogen-specific immune responses, identifying and studying
genetic determinants of host antibody responses or other as-
pects of immunity is challenging in humans. Demographic and
environmental factors such as viral dose and prior immune his-
tory affect immune responses to infection or vaccination (Lew-
nard and Cobey, 2018) and confound analyses. Furthermore, a
lack of replicates in outbred humans, as well as difficulties ac-
cessing relevant tissues, presents challenges for phenotyping
and mechanistic validation. Historically, mouse models have
been used to overcome many of the logistical, experimental,
and ethical issues that confound human studies. The genetic
tractability of the mouse genome, including the ready availability
of many gene-specific knockouts, and the ability to easily
generate new knockouts, has provided key insights into the
host pathways that control both development of the immune
system and the quality and durability of vaccine-induced immu-
nity (Li et al., 2008; Vidal et al., 2008). Increasingly, it is appreci-
ated that standard laboratory mouse strains do not recapitulate
the genetic diversity observed in the outbred human population
(Saul et al., 2019), and this lack of diversity has limited the utility
of themouse in identifying polymorphic genes and pathways that
contribute to the variation in the adaptive immune responses
observed in humans.
The Collaborative Cross (CC), a multi-parental mouse genetic
reference population, was developed to serve as a representa-
tivemammalianmodel of population-wide genetic diversity while
still providing the experimental tractability of the reproducible
inbred mouse (Churchill et al., 2004). CC strains have fixed and
known genomes, facilitating genetic mapping to identify quanti-
tative trait loci (QTLs) driving phenotypes of interest (Keele et al.,
2018). Studies across multiple pathogens have highlighted the
utility of the CC for studying infectious disease outcomes; CC
mice show disease phenotypes as diverse as their genetics,
facilitating discovery of novel and extreme phenotypes as well2 Cell Reports 31, 107587, April 28, 2020as in QTL mapping (reviewed in Noll et al., 2019). Furthermore,
use of the CC enables analysis of correlations between mapped
QTL and additional phenotypes across studies, extending the
ability to interpret the breadth of phenotypic effect of mapped
loci beyond the context in which they were originally mapped.
Relevant to this study, CC mice display a wide range of pheno-
types in response to challenge with IAV (Ferris et al., 2013;
Kollmus et al., 2018; Maurizio et al., 2017) as well as variation
in antibody glycosylation (Kristic et al., 2018).
To investigate the impact of host genetic variation on the hu-
moral immune response to IAV, we evaluated IAV-specific anti-
body responses over a broad infection time course across a
large set of F1 crosses between CC strains (CC-F1s). We
observed significant variation in antibody response to IAV across
these CC-F1s, including variation in the magnitude and kinetics
of virus-specific immunoglobulin M (IgM) and IgG, as well as IgG
subtype composition, and found these responses were highly
heritable. We identifiedmultiple genetic loci associated with vari-
ation in specific antibody subtypes at and across different time
points post-infection. We highlight themost significant and inter-
pretable loci, show that they have robust effects on antibody re-
sponses to other viruses, and identify candidate genes for each.
RESULTS
Antibody Response to IAV Varies across Genetically
Diverse Mice
To study the role of genetic factors in driving the magnitude, ki-
netics, and composition of the antibody response to IAV, we
measured IAV hemagglutinin (HA)-specific antibody levels
(henceforth referred to as IAV-specific antibody) in a large pop-
ulation of F1 crosses between CC strains (N = 116). This popula-
tion provided a reproducible population of heterozygous animals
to mimic the genetic heterozygosity of the human population
(see Data S1 for full list of the F1s with complete strain names
including laboratory codes). Our analysis focused on HA-spe-
cific antibody responses, as the bulk of the anti-IAV antibody
response is directed against the HA protein, and HA-specific
antibody responses are most correlated with protective neutral-
ization (Johansson et al., 1987). Female mice from 116 CC-F1s
were infected intranasally with IAV A/CA/04/09 (H1N1) and sacri-
ficed at multiple time points post-infection (3 mice per CC-F1 at
each time point for a total of1,350 mice). IAV-specific antibody
was measured from animals sacrificed at days 7, 10, 15, and 45
post-infection to capture both early and late humoral immune re-
sponses. IgM, IgG1, IgG2a+IgG2c (combined detection of sub-
types that segregate across mouse strains (Zhang et al.,
2012b)), IgG2b, IgG3, and total IgG were quantified from each
animal (a total of 8,000 antibody measurements across the
116 CC-F1s and 4 time points) to capture differential dynamics
of individual antibody subtypes and isotypes across our infection
time course.
Overall, IAV-specific antibody kinetics largely matched ex-
pected patterns. On average, IgM levels peaked early and then
declined, while IgG levels increased throughout our time course
(Figure 1A). However, as shown in Figure 1C, individual F1s var-
ied in overall levels and kinetics of the IAV-specific antibody
response, with some F1s displaying responses that were much
(legend on next page)
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CC018xCC009 versusCC036xCC051). A number of F1s showed
abnormal IgM responses, with later peaks (e.g., at day 15,
CC012xCC038 and CC032xCC017) or increasing through day
45 (e.g., CC011xCC032; Figure 1D). Other F1s were particularly
notable outliers more generally across isotypes. For example,
excluding its’ IgG1 levels, CC003xCC062 showed some of the
highest magnitude antibody responses at day 45 across iso-
types (Figure S1).
We next investigated the relationships between antibody sub-
types across the time points. Correlations between individual
subtypes at different time points were largely driven by temporal
kinetics, aside from IgM and some IgG1 responses that cluster
independently (Figure 1B). Interestingly, antibody composition
on days 7 and 15 clustered most similarly, followed by day 45
and lastly day 10. This clustering suggests that day 10 may
represent a unique inflection point in the antibody response
across the CC population, as opposed to a natural continuation
of the responses between days 7 and 15.
We also evaluated whether virus-induced disease correlated
with the antibody response. Similar to the variation in antibody
response (Figure 1), CC-F1s exhibited a wide range of disease
outcomes following IAV infection, ranging from asymptomatic
to severe weight loss and mortality (Figure S2). We have previ-
ously shown that these differences in disease susceptibility
can largely be attributed to variation in the IAV resistance gene
Mx1 (Maurizio et al., 2017), although other smaller effect loci
also contribute to variation in IAV susceptibility (Ferris et al.,
2013). Given the role of Mx1 in regulating both disease suscep-
tibility and viral load, we assessed whetherMx1 haplotype corre-
lated with the antibody response. Protective Mx1 haplotypes
(associated with decreased viral load and weight loss) showed
some relationship with decreased antibody response throughout
infection, with the strongest relationship seen early in infection
(days 7 and 10) and with IgG1 and IgG3 (Table S1). However,
these relationships waned over time and were not sufficient to
fully explain the variation in antibody responses we observed
throughout our study. In order to further clarify the role of Mx1
and viral load in influencing antibody responses, we measured
viral load by genome copy assay at day 2 post-infection for a
subset of CC-F1s selected for either high or low IgG responses
at day 10 post-infection. We observed no trend between viral
load and IgG levels on any day post-infection (Figure S3). We
also assessed whether the antibody response was associated
with IAV-induced disease as measured by maximal weight
loss, with control for Mx1 haplotype. We observed correlations
between maximal weight loss and the IgG1 response acrossFigure 1. The CC-F1 Population Exhibits Broad Between-Strain Vari
Antibody Responses
(A) The CC-F1 population generally exhibited an overall pattern of antibody respo
early and then waning, concurrent with a continual expansion of IgG isotypes). Ba
F1s.
(B) The correlation structure of antibody isotypes and subtype responses in t
development of various antibody types across the population.
(C and D) Representative examples of variation in the magnitude and kinetics of Ig
represents an individual mouse, and bars represent mean values for F1s. (D). This v
blue = Mx1 +/).
See also Figures S1–S3.
4 Cell Reports 31, 107587, April 28, 2020time points, in addition to with early IgM and late total IgG (Table
S2), with increased antibody levels associated with enhanced
weight loss. These observations suggest that there is a relation-
ship between antibody response and the severity of virus-
induced disease that is independent of Mx1-mediated effects.
Genetic Mapping Identifies Loci Associated with
Variation in Virus-Specific Antibody Response
IAV-specific antibody responses were significantly influenced by
genetic factors across isotypes/subtypes and time points, with
heritability estimates ranging from 26%–72% (median 44%; Ta-
ble S1). This roughly aligns with estimates reported in human
studies of antibody responses (Kimman et al., 2007). Antibody
responses were least heritable at day 7 (39% average across
isotypes) and most heritable at day 45 (57% average across iso-
types), suggesting that the early antibody response is more
driven by stochastic factors, while genetic factors play a pro-
gressively more important role later in the antibody response.
The exception to this trend was IgM, which was most heritable
at day 7 (56%), fitting with the classical kinetic profile of the
IgM response.
Given the high heritability of these antibody phenotypes, we
performed genetic mapping to identify QTLs (genomic regions
in which genotypes correlate with a phenotype of interest) asso-
ciated with variation in antibody response. We performed
genetic mapping on both total amount of antibody isotypes/sub-
types at single time points (i.e., days 7, 10, 15, and 45 individu-
ally) in addition to the kinetics (slope) between adjacent time
points (i.e., between days 7 and 10, 10 and 15, and 15 and 45)
to identify genetic factors contributing to variation in the overall
magnitude, composition, and kinetics of the antibody response.
Significant (genome-wide p < 0.05) and suggestive (genome-
wide p < 0.1) QTLs are summarized in Table 1 (see also Table
S3 for additional suggestive QTLs where p < 0.2). In total, we
mapped 2 significant QTLs and 21 suggestive QTLs for antibody
response to influenza (Ari1–Ari23) (Figure 2).
The majority of QTLs were mapped for individual subtypes at
given time points (16 QTLs) compared with responses between
time points (7 QTLs). At individual time points, the number of
QTLs mapped tracked with heritability, progressively increasing
from earlier to later time points (2 at day 7, 4 at day 10, 4 at day
15, and 6 at day 45) (Table S4). For kinetic measurements, the
majority of QTLs were mapped between days 15 and 45 (1 be-
tween days 7 and 10, 1 between days 10 and 15, and 5 between
days 15 and 45). IgM, the least abundant isotype, was mapped
least frequently (1 QTL), while IgG2a+IgG2c, the most abundant
subtype, was mapped most frequently (6 QTLs). The rest of theation in the Magnitude, Kinetics, and Composition of IAV-Specific
nses that is consistent with canonical antibody maturation (e.g., IgM peaking
r heights represent mean raw area under the curve (AUC) values across all CC-
he F1s over time was evaluated to determine the relationship between the
G (C) and IgM (D), with some exceptionally notable outliers for IgM. Each point
ariation was independent ofMx1 haplotype (for both panel sets red =Mx1/,
Table 1. Significant and Suggestive (p < 0.1) QTLs
Name Day Phenotype Chr p Value Start (Mb) Max (Mb) End (Mb) Haplotype Effects
Ari1 7 IgG2a+IgG2c 17 7.65E-02 47 52.6 54.4 low: NOD, WSB
Ari2 10 IgG3 11 2.80E-02 69.1 71.7 72.6 low: WSB
Ari3 15 IgM 8 8.15E-02 108.7 109.4 113.1 high: WSB
Ari4 15–45 IgG2b 5 3.95E-02 36.8 38.7 45.3 high: B6, NOD, NZO, PWK
low: AJ, 129, CAST, WSB
Ari5 15 IgG1 16 8.00E-02 40 40.6 44.7 high: CAST, PWK
low: AJ
Ari6 15 IgG2b 7 9.65E-02 109.1 114.3 115.5 high: NZO
Ari7 45 IgG3 9 7.35E-02 7.8 13.5 22.3 high: 129, NZO, CAST
low: AJ, B6, NOD, PWK
Ari8 15–45 TotalG 15 9.45E-02 51.6 53.2 55 high: PWK
low: CAST
See also Table S3.
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ped 4 times (Table S5).We identified evidence for complex archi-
tecture of specific responses (same phenotype, multiple QTLs),
as illustrated by Ari1 and Ari8, which were both mapped for
IgG2a+IgG2c at day 7 (Tables 1 and S3).While QTLswere largely
mapped acrossmany chromosomes, we also found evidence for
pleiotropy (same QTL, multiple phenotypes), as evidenced by
the overlap between Ari14-16 on chromosome 5. Importantly,
none of the QTL mapped to the Mx1 locus, which further sup-
ports the idea that, whileMx1 alleles may have some relationship
with antibody responses (Table S1), the genetic regulation of the
IAV-specific antibody response is predominantly independent of
Mx1.
We prioritized QTLs for follow-up candidate gene analysis
based on their genome-wide significance as well as clarity of
haplotype effects. From the 8 QTLs with p < 0.1, we focused
on 4 QTLs, Ari1–Ari4 (Figure 3). Ari1 (chromosome 17 [chr17]:
46.1–54.5 Mb, p = 0.0765) was mapped for IgG2a+IgG2c at
day 7 post-infection and accounts for 4.5% of the total pheno-
typic variation (15.2% of heritable variation), driven by a low
response from F1s with WSB/EiJ and NOD/ShiLtJ haplotypes
at the locus. Ari2 (chr11: 69.1–72.6 Mb, p = 0.028) was mapped
for IgG3 at day 10 post-infection and accounts for 9.8% of the
total phenotypic variation (30.7% of heritable variation), driven
by a low response from F1s with a WSB/EiJ haplotype at the lo-
cus. Ari3 (chr8: 108.7–113.1 Mb, p = 0.0815) was mapped for
IgM at day 15 post-infection and accounts for 5.8% of the total
phenotypic variation (14.8% of the heritable variation), driven
by a high response from F1s with a WSB/EiJ haplotype at the lo-
cus. Finally, Ari4 (chr5: 37.0–46.1 Mb, p = 0.0395) was mapped
for change in IgG2b between days 15 and 45, with less change
between time points in F1s carrying 129S1/SvImJ, A/J, CAST/
EiJ, and WSB/EiJ haplotypes at the locus.
Antibody response loci may be specifically associatedwith the
mapped phenotype of interest (e.g., IAV-specific IgG3) or reflect
a broader effect on immune system development or response.
Therefore, we interrogated the extent to which Ari1–Ari4 haplo-
types further correlated with other aspects of IAV-induced pa-
thology or immune responses in our CC-F1 population.We reduced the number of states being analyzed from the 8 in-
dependent founder haplotypes used in our QTL mapping anal-
ysis to the 2 variant haplotype groups (e.g., high or low response)
at the locus, thereby enhancing power to detect less strong
phenotypic associations. None of the Ari loci showed correla-
tions with gross IAV-induced disease as measured by weight
loss, with control for Mx1 haplotype (Table S4).
The Ari loci showed numerous significant correlations with
additional IAV-specific antibody isotypes and time points. Ari1
(IgG2a+IgG2c, day 7) showed broad correlations acrossmultiple
isotypes at days 7, 10, and 15. Additionally, the association be-
tween Ari1 and IgG1 persisted through day 45 (Table S1). This
suggests that Ari1 plays a role in the early antibody response
that carries over through the mid-stage response, with a unique
persistent effect on IgG1. Ari2 (IgG3, day 10) was broadly corre-
lated with the antibody response at day 7 but showed the stron-
gest correlations at day 10 and was also associated with total
IgG through days 15 and 45 (Figure 4), suggesting that Ari2
broadly impacts the overall early antibody response with some
prolonged effect. Ari3 (IgM, day 15) also broadly correlated
with the antibody response at day 7, including a strong correla-
tion with total IgG. Ari3was correlated with IgG2a+IgG2c and to-
tal IgG day 15 post-infection, suggesting that Ari3 is a driver in
the early-to-mid stage antibody response for both IgG and IgM
(Table S1). When tested across individual time points, Ari4
(IgG2b, ratio between days 15 and 45) showed associations
with multiple isotypes, including IgG2b, at day 15, but not day
45 (Table S1), indicating that the association between Ari4 and
temporal changes in IgG2b levels are predominantly driven by
effects on antibody isotype levels on day 15.
To further assess the role of Ari1–Ari4 in virus-specific anti-
body responses, we tested to see if Ari1–Ari4 haplotypes were
associated with antibody responses to other viruses. For this
analysis, we took advantage of existing datasets from related
but independent studies with SARS-CoV, a respiratory virus,
and chikungunya virus (CHIKV), an arbovirus. In the SARS-CoV
study, mice from a similar panel of CC-F1s were infected with
SARS-CoV, and antibody response to the spike (S) protein was
measured at days 7, 15, and 29 post-infection. An additionalCell Reports 31, 107587, April 28, 2020 5
Figure 2. Multiple Loci Drive Antibody Responses
to IAV
QTLmapping allowed us to identify 23 loci contributing to
the antibody response composition, magnitude, and ki-
netics. We summarize these loci (Ari1–Ari23) in a chro-
mosomal ideogram showing their positions, as well as the
antibody type and the time point for which they were
mapped on their corresponding genomic loci.
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Figure 3. Representative Ari QTLs Associated with Variation in IAV-Specific Antibody Responses
(A–C) show Ari1, D–F show Ari2, G–I show Ari3, and J–L show Ari4.
(A, D, G, and J) Phenotypic distributions for the traits mapped to Ari1–Ari4, respectively. Each plot is independently ordered by the CC-F1 means for that trait
(black points) and also shows the individual mice (purple points). The exception is (J), which only showsmean values, as the ratios of antibody response between
time points were calculated using the mean value for each F1 at the relevant individual time points.
(B, E, H, and K) show the associated QTL LOD plots (significance score across the genome) forAri1–Ari4. Significance thresholds are shown in red (genome-wide
p = 0.05), blue (p = 0.1), and green (p = 0.2). Following identification of QTLs, we determined the causal haplotypes driving these responses (C, F, I, and L). Each
plot is zoomed in to the relevant QTL loci on the x axis. The lower black line shows the LOD score for that region, and the colored lines display the estimated effect
of each of the 8 CC founder haplotypes (A/J = yellow, C57BL/6J = gray, 129S1/SvImJ = pink, NOD/ShiLtJ = dark blue, NZO/HlLtJ = light blue, CAST/EiJ = green,
PWK/PhJ = red, andWSB/EiJ = purple). Causal haplotype groups are determined based on direction and distance frommean effect and the largest split distance
between lines (e.g., in I, the WSB line is furthest away from all others).
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Figure 4. Ari2 Shows Broad Effects on IAV-Specific Antibody Responses in the CC-F1 Population
We assessed the impact that a WSB/EiJ haplotype (x axis; 1 = one WSB haplotype; 2 = two non-WSB haplotypes) have on other IAV antibody responses in this
study (y axis: CC-F1 mean levels of transformed AUC levels for given isotypes/time points). Points represent mean values for CC-F1s, with ~3 mice per CC-F1.
Annotations refer to transformations applied to datasets (*p < 0.1, **p < 0.05, ***p < 0.01).
See also Table S1.
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OPEN ACCESSmeasurement was taken 4 days following a secondary challenge
(‘‘rechallenge’’), which was administered at day 28 post-primary
infection. Ari1 haplotypes were not associated with SARS-CoV-
specific antibody responses (Table S6). In contrast, Ari2 haplo-
type showed broad associations with antibody specific to
SARS-CoV at days 7 and 29, and with IgM at all time points
post-primary and secondary challenge (Table S6). Ari3 haplo-
type showed only a few correlations with SARS-CoV antibody,
which were not indicative of trends either across isotypes or
time points (Table S6). Ari4 showed the strongest correlations
with the SARS-CoV-specific antibody response, most potently
at day 7 but lasting through days 15 and 29 (Table S6). In the
CHIKV study, mice from a panel of 64 inbred CC strains were in-
fected with CHIKV. Virus-specific IgM, IgG, and neutralizing anti-
body were measured at day 7 post-infection. While Ari1, Ari2,
and Ari4 did not correlate with the CHIKV-specific antibody
response (IgM, IgG, and neutralization titer) in CC-RI mice at
day 7 post-infection, Ari3 haplotypes showed strong associa-
tions with the CHIKV antibody response (Table S6). Interestingly,
these associations were in the opposite direction as observed for
IAV (i.e., WSB/EiJ haplotype associated with decreased anti-8 Cell Reports 31, 107587, April 28, 2020body response). Overall, these findings suggest that Ari1 is
uniquely associated with variation in IAV-specific antibody re-
sponses, while Ari2–Ari4 show broader effects on virus-specific
antibody responses. Ari2 and Ari4 are associated with variation
in SARS-CoV-specific antibody responses, while Ari3 was also
found to be strongly associated with variation in the CHIKV-spe-
cific antibody response.
Candidate Gene Analysis
To identify candidate genes at each of the loci, we applied a
series of criteria to filter through the variants (Figure 5). We first
conducted association testing as implemented in the R package
DOQTL (Gatti et al., 2014), comparing the pattern of single-
nucleotide polymorphisms (SNPs) at each marker within the
QTL to the observed haplotype effects at the corresponding
location, and filtering out variants below the LOD threshold.
Next, candidate SNPs were categorized based on the classifica-
tion of the affected genetic element (e.g., regulatory region,
protein-coding gene, or non-coding RNA). While variation in
regulatory regions, microRNAs (miRNAs), long non-coding
RNAs (lncRNAs), or other genetic elements may drive QTLs,
Figure 5. Pipeline to NarrowDownCandidate Genes under Ari1–Ari4
Variants under each QTL were considered if they were above the association
testing threshold and were contained in a protein-coding gene. Protein-coding
genes were then evaluated based on whether they were expressed in the lung
or immune tissue. Using a separate transcriptional dataset from 11 CC strains
infected with H3N2 influenza, IAV-specific and haplotype-specific differential
expression was evaluated. Genes were considered if they had non-synony-
mous coding variants or splice region variants or showed haplotype-specific
expression.
See also Figure S4 and Table S7.
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they have more interpretable and better defined functional con-
sequences. The protein-coding genes at each locus were next
evaluated based onwhether the gene exhibited baseline expres-
sion in the lung or immune tissue (i.e., spleen or thymus) utilizing
ENCODE data (Yue et al., 2014).
We next evaluated candidate genes based on the predicted
consequences of their variants, which were determined using
the Ensembl Variant Effect Predictor (McLaren et al., 2010).
Genes with non-synonymous coding variants and splice variants
were included as candidates. To assess the relevance of non-
coding variants, which were determined most likely to have a
role in differential expression, we leveraged transcriptional data-
sets from lungs and peripheral blood of 11 CC strains, which
were either mock-infected or infected with IAV H3N2 (days 3
and 5 post-infection for lung; days 3, 5, and 8 for blood). We
applied this data to assess if genes with non-coding variants
were differentially expressed between haplotype groups (see ex-
amples in Figure S4). By applying these criteria, we identified a
set of high-priority candidate genes (Table 2).
Ari1 contains 139 genetic elements (e.g., protein-coding
genes, large intergenic noncoding RNAs [lincRNAs], retained in-
trons, pseudogenes) (25,732 SNPs), which was narrowed to 15
genetic elements (100 SNPs) above the association threshold
(LOD > 3.2) (Table S7), and then to six protein-coding genes
(46 SNPs), five of which were expressed in relevant tissues. All
of these candidate genes contained non-coding variants, while
none of the SNPs resulted in non-synonymous coding changes
or splice variants. Analysis of haplotype-specific expression
found while none of the candidates showed haplotype-specific
expression in the lungs, one gene, unc-5 family C-terminal like
(Unc5cl or Zud), showed haplotype-specific expression in theperipheral blood, making Unc5cl the lead candidate gene under
the locus.
Ari2 contains 99 genetic elements (11,236 SNPs), which was
narrowed to 40 genetic elements (286 SNPs) above the
association threshold (LOD > 4) (Table S7) and then to 20 pro-
tein-coding genes (166 SNPs), 18 of which were expressed in
relevant tissues. One of these genes (NOD-like receptors, pyrin
domain containing 1B [Nlrp1b]) had non-synonymous variants
and splice variants and showed haplotype-specific expression
in the lung. Two genes had both non-synonymous variants and
haplotype-specific expression in the lung (WSC domain contain-
ing 1 [Wscd1] and RPA-interacting protein [Rpain]). Three
additional genes under Ari2 with non-coding variants showed
haplotype-specific expression in the lung (spinster homolog 3
[Spns3], MIS12 kinetochore complex component [Mis12], and
nucleoporin 88 [Nup88]).
Ari3 contains 82 genetic elements (14,707 SNPs), which was
narrowed to 57 genetic elements (607 SNPs) above the
association threshold (LOD > 2.85) (Table S7) and then to 40 pro-
tein-coding genes (565 SNPs), 30 of which were expressed in
relevant tissues. UnderAri3, there were four genes with non-syn-
onymous coding variants (breast cancer anti-estrogen resis-
tance protein 1 [Bcar1], HYDIN axonemal central pair apparatus
protein [Hydin], polycystic kidney disease 1 like 3 [Pkd1l3], and
zinc-finger homeobox 3 [Zfhx3]). There were two additional
genes with splice variants (lysyl-tRNA synthetase [Kars] and
mixed lineage kinase domain-like [Mlkl]). We were not able to
evaluate Ari3 non-coding candidates based on haplotype-spe-
cific expression due to a lack of representation of the WSB/EiJ
haplotype at Ari3 in the strains included in the transcriptional
dataset.
Ari4 contains 22 genetic elements (4,899 SNPs), which was
narrowed to 16 genetic elements (68 SNPs) above the associa-
tion threshold (LOD > 0.597) (Table S7) and then to six protein-
coding genes (51 SNPs), all of which were expressed in relevant
tissues. Under Ari4, 4 genes with non-coding variants showed
haplotype-specific expression in the lung (coiled-coil and C2
domain containing 2A [Cc2da2], LIM-domain-binding protein 2
[Ldb2], Prominin 1 [Prom1], and transmembrane anterior poste-
rior transformation 1 [Tapt1]).
DISCUSSION
The humoral immune response is an important component of
protection against viruses such as IAV. However, studying the
role of the genetic factors that contribute to regulation of the anti-
body response is challenging in humans due to confounding de-
mographic and environmental variables, as well as the relatively
late stage in infection when the humoral response occurs. To
study the role of host genetics in driving the antibody response
to IAV, we used a diverse panel of CC-F1s and found that CC
mice exhibit high levels of variation in susceptibility to disease
as well as the generation and maintenance of specific antibody
isotypes and subtypes. In concordance with human studies
(Kruskall et al., 1992; Linnik and Egli, 2016; Ovsyannikova
et al., 2012), we found strong evidence for genetic control of
these traits (median heritability, 44%) and were able to mapmul-
tiple loci associated with antibody responses.Cell Reports 31, 107587, April 28, 2020 9
Table 2. High-Priority Candidate Genes Identified under Ari Loci based on Evaluation Criteria
QTL Gene
Coding
Variant
Splice
Variant
UTR
Variant
Other
Non-
coding
Variant
Lung or
Immune
Tissue
Expression
IAV-Induced Differential
Expression
Haplotype-Specific
Expression
Criteria MetLung Blood Lung Blood
Ari1 Unc5cl NA NA NA yes yes no yes no yes non-coding
Ari2 Mis12 NA NA 30, 50 yes yes yes no yes yes non-coding
Ari2 Nlrp1b Mis Yes NA yes yes yes yes yes no coding, non-coding
Ari2 Nup88 NA NA NA yes yes yes yes yes no non-coding
Ari2 Rpain Mis NA NA yes yes no yes yes no non-coding
Ari2 Spns3 Syn NA NA yes yes yes no yes no non-coding
Ari2 Wscd1 Mis NA NA yes yes yes no yes no coding, non-coding
Ari3 Bcar1 Mis NA NA yes yes yes yes NA NA coding
Ari3 Hydin Mis NA NA yes yes yes no NA NA coding
Ari3 Kars Syn yes 30, 50 yes yes yes yes NA NA splice
Ari3 Mlkl NA yes NA yes yes yes yes NA NA splice
Ari3 Pkd1l3 Non NA NA yes yes no yes NA NA coding
Ari3 Zfhx3 Mis NA NA yes yes yes yes NA NA coding
Ari4 Cc2d2a NA NA NA yes yes yes no yes no non-coding
Ari4 Ldb2 NA NA NA yes yes yes no yes no non-coding
Ari4 Prom1 NA NA NA yes yes yes yes yes no non-coding
Ari4 Tapt1 NA NA 30 yes yes no yes yes no non-coding
High priority candidate genes were identified based on evaluation criteria illustrated in Figure 5. (UTR, untranslated region; Mis, missense; Non,
nonsense; Syn, synonymous). See also Figures S4 and S5 and Table S7.
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phenotypic discovery and model development. Unique combi-
nations of alleles present in CC mice may present as novel phe-
notypes, which can provide an opportunity to study interesting
disease features and/or more closely model human disease
(Rasmussen et al., 2014; Rogala et al., 2014). We identified mul-
tiple CC-F1s with outlier antibody response phenotypes in our
investigation, including multiple F1s with persistent IAV-specific
IgM responses. Importantly, those F1s with persistent IgM re-
sponses were not defective in IAV-specific IgG responses, and
some had protective Mx1 alleles, suggesting that the sustained
IgM response was not due to failure in class switching or inability
to control viral replication. Notably, two highlighted CC-F1s with
persistent IgM responses shared the parental strain CC032, sug-
gesting that genetic contributions from CC032 (independent of
Ari3, for which CC032 has the low-response haplotype) may
be involved in longer lasting IgM responses. Such outlier strains
can be used to model these aberrant responses and/or included
in future targeted mapping studies (e.g., F2 crosses).
All antibody response measures were driven to varying de-
grees by genetically variable (e.g., heritable) effects; however,
not all phenotypes were mapped to QTL. This issue of ‘‘missing
heritability’’ (the inability to identify all the genetic factors that
contribute to heritable variation) is prevalent across genetic
mapping studies. Missing heritability can be explained by
numerous factors, including lack of sufficient power or informa-
tive lines to detect variants of small effect, phenotypic heteroge-
neity (i.e., same phenotype, different cause), complex genetic
architecture, and blindness to genetic features such as copy
number variants or epigenetic modifications (Manolio et al.,10 Cell Reports 31, 107587, April 28, 20202009). More targeted studies, such as 2-strain intercrosses,
allow for a more complete discovery of phenotypic modulation
with greater power to identify more complex genetic interactions
such as epistasis (Gralinski et al., 2017; Rogala et al., 2014).
Nonetheless, we had sufficient power to identify major loci with
effects across our CC-F1 population.
We further investigated our mapped QTLs to identify broader
relationships with additional phenotypes to further assess the
breadth of effect of each QTL. When testing for further associa-
tions with Ari1–Ari4 haplotypes across antibody datasets (IAV,
SARS-CoV, and CHIKV), rather than focusing on any individual
association, we were interested in robust and persistent trends
in correlations across isotypes and/or time points. This is critical
due to the differing heritability and potential genetic architecture
across isotypes and time points. Therefore, while we did not uti-
lize false discovery rate or multiple-test corrections in assessing
these relationships, these trends are indicative of important rela-
tionships that merit further study. Furthermore, consideration of
these trends, or lack thereof, can provide insight into possible
mechanisms by which the genes driving QTL impact the anti-
body response. Ari1 showed broad effects on the early antibody
response to IAV only and was not associated with antibody
response to SARS-CoV or CHIKV, suggesting that it may be
involved with specific responses to IAV such as innate immune
recognition and response or antigen presentation. Ari2 showed
broad early effects with IAV as well as SARS-CoV-specific re-
sponses, suggesting that the underlying gene is involved in early
stages of infection or immune response for respiratory patho-
gens. Ari3 also showed broad early effects with IAV and a strong
correlation with antibody response to CHIKV, though the
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different viruses. Ari4 was most relevant for day 15 antibody
response to IAV and also showed strong associations with anti-
body response to SARS-CoV, suggesting that it may be widely
relevant for the development of the humoral response. These
broad associations highlight the utility of the CC as a resource
to extend analyses into related datasets to gain further under-
standing of the role of loci across phenotypes while illustrating
the need for future work to define the specific mechanisms by
which each of these loci affect antiviral antibody response.
In addition to impacting the scope of pathogens for which a
QTL may play a role, the mechanisms by which these loci
mediate antibody response to primary H1N1 infection is also
relevant for their potential to affect antibody response to other
strains of IAV or even IAV vaccination. QTLs that are driven by
genes involved in early innate response in the lung aremore likely
to be specific to primary infection and may also be virus-strain
specific (Ryan et al., 2018). Alternatively, QTLs that appear to
be more generally involved in the later humoral response, such
as Ari4, may be more likely to have a broader effect that is rele-
vant for other IAV strains and vaccination.
Ultimately, the goal of genetic mapping studies is to identify
the causal genes and variants driving phenotypic differences. In-
sights into possible mechanisms gained from analyzing broad
associations across an array of phenotypes can help guide se-
lection of candidate genes, along with other considerations
such as gene classification, predicted consequence of muta-
tions, expression in relevant tissues, and any known relevance
in infection and/or immunity. We leveraged a transcriptional da-
taset from lungs and blood of CC strains infected with IAV H3N2,
which allowed us to assess haplotype-specific expression of
candidate genes in the context of the relevant tissue systems.
These results were able to help us to narrow our focus on smaller
sets of genes (as shown in Figure 5). However, it is possible that
due to disease kinetics, the tissue complexity, and our above-
discussed description of strain-differences, this analysis is
overly restrictive.
Under Ari1, we identified one candidate gene, Unc5cl (Zud),
which showed flu-induced and haplotype-specific expression
in the peripheral blood, but not the lungs. While the function of
Unc5cl is largely unknown, it contains a death domain and has
been shown to be involved in the regulation of nuclear factor
kB (NF-kB) (Heinz et al., 2012; Zhang et al., 2004). To our knowl-
edge, a role of Unc5cl in host response to viral infection has not
been evaluated, and this gene presents a clear candidate for
additional analysis.
Under Ari2, we identified 6 candidate genes (Mis12, Nup88,
Nlrp1b, Rpain, Spns3, and Wscd1). There is no documented
role in immunity for Wscd1 or Mis12. Rpain (also known as RIP
andHRB) has been shown to play an important role in the nuclear
export of viral ribonucleoproteins (vRNPs) during IAV replication
via interaction with the IAV nuclear export protein NS2. Spns3
is highly expressed in the spleen and thymus, and its paralog,
Spsn2, has been shown to be important for lymphocyte develop-
ment and humoral immune response (Nijnik et al., 2012). Nup88
has been shown to be important for MX2 inhibition of HIV (Dicks
et al., 2018), and its Drosophila paralog is involved in innate im-
mune activation (Uv et al., 2000). Nlrp1b is an inflammasomegene, of which different genetic variants have been shown to
play a role in susceptibility to anthrax lethal toxin (Moayeri et al.,
2010), although it has not been previously linked to viral infection.
Under Ari3, we identified 6 candidates genes with non-synon-
ymous or splice region variants (Bcar1, Hydin, Kars, Mlkl, Pkd1l3,
andZfhx3).Bcar1 and Zfhx3 have no established role in immunity
or viral infection. Hydin function is important for ciliary projec-
tions and motility, which could affect influenza tropism (Lech-
treck et al., 2008; Smith et al., 2019). Kars (also known as LysRS)
encodes a tRNA synthetase, which plays a fundamental role in
protein translation in addition to acting as a signaling molecule
that responds to immunological stimulation (Yannay-Cohen
et al., 2009). Mlkl encodes a protein that plays a critical role in
necroptosis, and its activity is enhanced by interaction with the
NS1 protein of IAV (Gaba et al., 2019). Pkd1l3 encodes a calcium
channel component and is largely conserved across classical
inbred strains but has a unique nonsense mutation in the WSB
allele (which drives the QTL effect).
We were unable evaluate haplotype-specific expression for
genes under Ari3 due to a lack of haplotype representation in
our transcriptional dataset. However, there are several genes
with non-coding variants under the interval that could be consid-
ered additional candidates based on precedence in the literature.
DEADboxpolypeptide 19b (Ddx19b) inhibits type I interferon (IFN)
and is required for IAV replication via a role in nuclear export of
vRNPs (Diot et al., 2016; Zhanget al., 2019). Dihydroorotate dehy-
drogenase (Dhodh) is involved in pyrimidine synthesis, and
DHODH inhibitors have been shown to have strong antiviral activ-
ity against influenza and other viruses (Cheung et al., 2017; Zhang
et al., 2012a). Gamma-aminobutyric acid A receptor-associated
protein-like 2 (Gabarapl2, also known as Gate-16) plays a role in
autophagy and IFN-g-dependent antimicrobial response (Sasai
et al., 2017). Haptoglobin (Hp) is involved in MyD88-dependent
inflammation, which plays an important role in primary influenza
infection (Seo et al., 2010), and deficiency leads to impaired
lymphocyte development and adaptive immune response (Hun-
toon et al., 2008; Shen et al., 2012). Despite the lack of haplo-
type-specific expression data, these genes may warrant further
evaluation as potential candidate genes under Ari3.
Under Ari4, we identified 4 candidates of interest: Lbd2,
Prom1,Cc2da2, and Tapt1. Neither Lbd2 nor Prom1 has a docu-
mented role in immunity. Cc2da2 is required for cilia biogenesis,
which as previously mentioned may be relevant for influenza
tropism (Smith et al., 2019; Veleri et al., 2014). Tapt1 is also
important for ciliogenesis, and knockdown has been shown to
decrease IAV replication (Sui et al., 2009; Symoens et al.,
2015). Notably, multiple candidate genes under the Ari loci
have roles in ciliary function (Hydin, Cc2da2, and Tapt1). Human
patient cohorts have shown co-occurrence of primary ciliary
dyskinesia and humoral immunodeficiency, both rare disorders,
suggesting a possible common pathophysiological pathway be-
tween ciliary function and antibody response (Boon et al., 2014).
Tapt1 has also been shown to be differentially expressed in the
context of other respiratory pathogens (Denisenko et al., 2019)
and was identified in a gene set associated with increased HA in-
hibition and neutralization titers following influenza vaccination
(Ovsyannikova et al., 2016), further supporting a potential role
for this gene in driving Ari4.Cell Reports 31, 107587, April 28, 2020 11
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challenges. This is exemplified by Ari2, under which Nlrp1b
was identified as the strongest candidate gene, carrying haplo-
type-specific coding variants predicted to be strongly delete-
rious to the encoded innate immune sensor. However, analysis
of this gene and interpretation of expression data is challenging
because of the newly described genetic complexity of the locus;
multiple Nlrp1 paralogs and haplotypes sort across mouse
strains and have not been fully characterized (e.g., WSB/EiJ
mice carry 5 Nlrp1 paralogs, only 2 of which are shared with
the reference C57BL/6J) (Lilue et al., 2018). Upon IAV infection,
Nlrp1b knockout mice did not show significant differences in
antibody response (Figure S5). While this lack of phenotype
might suggest that Nlrp1b is not causal for the Ari2 phenotype,
it is equally likely that the specific Nlrp1b allelic variant in the
CC, or one of the Nlrp1 paralogs, is responsible for the effect
of Ari2. Continued work to deconvolute the mouse genome
across genetically diverse strains, as well as advances in molec-
ular and genetic tools such as CRISPR, will facilitate follow-up
analyses on such complex loci.
Other potential challenges remain in the identification and vali-
dation of genes that regulate the antibody response to IAV.
Notably, we studied IAV exposure in naive animals, whereas
prior infection (especially with IAV) is a large factor in shaping
the humoral immune response in humans (Lewnard and Cobey,
2018). Nonetheless, we identified multiple loci with genes that
overlap with human mapping studies of antibody response or
influenza infection. Ari1 contains kinesin family member 6
(Kif6), which was identified in a human study of antibody
response to smallpox vaccination (Ovsyannikova et al., 2012).
Kif6 did not meet our formal candidate criteria as its coding
variant was synonymous and it did not show haplotype-specific
expression in the dataset that we utilized. Additionally, Ari2 con-
tains two genes that were identified in a human study of severe
pneumonia associated with H1N1 influenza infection (Zu´n˜iga
et al., 2012), Rpain and complement component 1 Q subcompo-
nent-binding protein (C1qbp), a high-affinity receptor for the
complement protein C1q that is important for dendritic cell matu-
ration (Gotoh et al., 2018). While Rpain met our criteria as a
candidate gene, and is therefore a high-priority candidate for
additional analysis, C1qbp1 had a non-coding variant, but did
not show haplotype-specific expression in the lungs or blood.
Lastly, as noted above, Tapt1 under Ari4 has been associated
with variation in antibody responses to IAV vaccination in hu-
mans (Ovsyannikova et al., 2016), making this gene a high-prior-
ity candidate for additional study. While not all of these genes
made it through our formal selection criteria, this concordance
between loci mapped in our study and in human studies demon-
strates the translational relevance of our work, and we are opti-
mistic that other loci mapped here could be validated and impor-
tant in humans.
Conclusions
The magnitude and kinetics of the antibody response to IAV
varies greatly across a genetically diverse set of CC-F1 mice.
These differences, which did not widely correlate with general
susceptibility to IAV-induced disease, were leveraged to map
23 QTLs associated with variation in specific antibody isotypes12 Cell Reports 31, 107587, April 28, 2020across time points. Multiple significant and suggestive QTLs
were identified, including Ari1–Ari4, which likely drive variation
in IAV-specific antibody response through different mecha-
nisms. Ari loci also showed effects on the antibody response
to SARS-CoV and CHIKV, suggesting that these QTLs are
broadly important for antibody response to multiple pathogens.
Candidate genes for Ari loci have been identified and show over-
lap with genes identified in human studies. Overall, our findings
demonstrate that multiple independent loci regulate the magni-
tude, kinetics, and composition of IAV-specific antibody. These
results further demonstrate the utility of the CC for modeling
how host genetic variation shapes pathogen-specific immunity
and open the door to more robust modeling of the complex inter-
play between genetics and environment in promoting protective
adaptive immune responses to pathogens.
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The antibody datasets generated and used during this study are available at Mendeley Data (https://dx.doi.org/10.17632/
kxr3t8n384.1). Lung and blood expression datasets are available through the Gene Expression Omnibus (GSE136748, GSE110384).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Ethics statement
University of North Carolina at Chapel Hill
Mouse studies were performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory An-
imals of the National Institutes of Health. All mouse studies at UNC (Animal Welfare Assurance #A3410-01) were performed using
protocols approved by the UNC Institutional Animal Care and Use Committee (IACUC) in a manner designed to minimize pain
and suffering in infected animals. Any animals that exhibited severe disease signs was euthanized immediately in accordance
with IACUC approved endpoints.
Helmholtz Centre for Infection Research
All experiments in mice were approved by an external committee according to the national guidelines of the animal welfare law in
Germany (BGBl. I S. 1206, 1313 and BGBl. I S. 1934). The protocol used in these experiments has been reviewed by an ethics com-
mittee and approved by the relevant authority, the ‘Niedersa¨chsisches Landesamt f€ur Verbraucherschutz und Lebensmittelsicher-
heit, Oldenburg, Germany’ (Permit Numbers: 33.9.42502-04-051/09 and 3392 42502-04-13/1234).
Mice
IAV H1N1
Mice from 64 CC strains were purchased from the UNC Systems Genetics Core Facility (SGCF) between July 2012 and July 2016.
Femalemicewere generated from 116CC-F1 crosses between these 64CC strains (see Data S1 for full list). All micewere housed in a
specific pathogen free facility under standard conditions (12hr light/dark, food and water ad libitum) at UNC Chapel Hill. Female mice
of 8-12 weeks of age at time of experiment were used. Nlrp1b KO and C57BL/6J mice were purchased from Jackson Laboratories
and bred in our colony at UNC Chapel Hill. F1 or F2 heterozygous animals were bred to generate a single experimental cohort with
littermate controls. Male and female mice were used and infected when mice were between 9-11 weeks of age.
IAV H3N2
Mice from 11 CC strains (see Data S1 for full list) were received from the UNC SGCF and then bred in the animal facility of the Helm-
holtz Centre for Infection Research, Braunschweig under specific pathogen free conditions. Femalemice of 8-12weeks of age at time
of experiment were used.
SARS-CoV
Mice from 64 CC strains were purchased from the UNC SGCF between July 2012 and July 2016. Female F1 mice were generated
from 116CC-F1 crosses between these 64CC strains (see Data S1 for full list). All micewere housed in a BSL-3 facility at UNCChapel
Hill. Mice were 8-12 weeks of age at time of experiment.
CHIKV
Female mice from 64 CC strains (see Data S1 for full list) were housed under BSL-3 conditions at UNC Chapel Hill. Mice were
6-7 weeks old at time of experiment.
Cell lines
HEK293T (ATCC) were used for the propagation of IAV H1N1. MDCK cells (ATCC) were used for the amplification and titration of IAV
H1N1. MDCK II cells (ATCC) were used for the titration of IAV H3N2. Vero E6 cells (ATCC) were used for the titration of SARS-CoV.
Vero cells (ATCC) were used for the titration of CHIKV and FRNT50 assays. All cells were maintained at 37C in standard growth me-
dia. Serum-free media was used for propagation, amplification, and titration of IAV.
METHOD DETAILS
Virus
IAV H1N1
Influenza A/CA/04/09 (H1N1) was generated by multi-plasmid transfection of HEK293T cells followed by 48 hour amplification and
titration in MDCK cells as described previously (Neumann et al., 2012).
IAV H3N2
Mouse-adapted A/Hong Kong/01/68 (H3N2) virus was originally obtained fromOtto Haller, University of Freiburg (Haller et al., 1979).
Virus was propagated as described previously (Wilk and Schughart, 2012). Titer was determined by focus forming unit assay (FFU/ml)
in Madin-Darby Canine Kidney II (MDCK) cells (ATCC).
SARS-CoV
Recombinant mouse-adapted SARS-CoV MA15 (mouse adapted SARS-CoV Urbani strain) was propagated and titered on Vero E6
cells. All experiments were performed in a certified BSL-3 laboratory.e3 Cell Reports 31, 107587, April 28, 2020
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The SL15649 clinical isolate of CHIKV was derived from the pMH56.2 infectious clone and titered on Vero cells, as described pre-
viously (Morrison et al., 2011).
Infections
IAV H1N1
Micewere lightly anesthetized via isoflurane inhalation and infected intranasally with either 5000 focus forming units (FFU) of influenza
A/CA/04/09 in 50mL PBS or PBS only (mock-treatment). Approximately 3 mice per F1 per time point were infected with IAV. Animals
were measured daily for weight loss and monitored for mortality and clinical disease scores. At 2, 4, 7, 10, 15, or 45 days post-infec-
tion, animals were euthanized via isoflurane overdose and bilateral thoracotomy. Lungs for viral load were collected at day 2 post-
infection and stored in RNAlater (Applied Biosystems/Ambion, Austin, TX) at 80C after 1 day at 4C. Blood was collected by ter-
minal bleed, and serum was aliquoted and stored at 40C or80C. For Nlrp1b studies, all mice were infected with IAV and serum
was collected by submandibular bleed at day 10 post-infection.
IAV H3N2
Mice were anesthetized by intra-peritoneal injection with Ketamine/Xylazine (85% NaCl (0.9%), 10% Ketamine, 5% Xylazine) and
infected intranasally with 20ml virus solution (10 FFU) in PBS or PBS only (mock-treatment). 3-4 mice per strain per time point and
treatment were infected. Body weight, survival and well-being of mice were monitored. Lungs were harvested from sacrificed
mice at days 3 and 5 post-infection. Blood was collected by retro-orbital bleed at days 3, 5, and 8 post-infection.
SARS-CoV
Mice were lightly anesthetized via isoflurane inhalation and infected intranasally with 5x103 plaque forming units (PFU) of MA15 in
50mL PBS or PBS only (mock-treatment). Approximately 3 mice per F1 per time point were infected with SARS-CoV. Animals
were measured daily for weight loss and monitored for mortality and clinical disease scores. At 7, 15, or 29 days post-infection, an-
imalswere euthanized via isoflurane overdose and bilateral thoracotomy. Another group of animals was re-challenged at day 28 post-
infection, and euthanized at day 32 (4 days post-re-challenge). Blood was collected by terminal bleed, and serum was aliquoted and
stored at 80C.
CHIKV
Micewere infected with 100 PFU of CHIKV SL15649 in a 10ml volume via the subcutaneous route in the left rear footpad, or PBS alone
(mock treatment). Three mice per group were infected and two per group received mock treatment. Mice were euthanized on day 7
post infection and serum was collected and stored at 80C.
Viral load measurement
Lung tissue was thawed on ice and transferred to Trizol (Invitrogen, Carlsbad CA) preceding homogenization and RNA extraction
using the QIAGENmiRNeasy mini kit (QIAGEN, Hilden, Germany, 217004). One-step RT-PCRwas performed to quantify IAV (F: GAC
CRATCCTGTCACCTCTGAC. R: AGGGCATTYTGGACAAAKCGTCTA, Probe: TGCAGTCCTCGCTCACTGGGCACG, Reporter:
FAM) and 18S (4319413E, Applied Biosystems, Foster City, CA) in duplex. Delta CT values were calculated as the difference between
IAV and 18S CT values.
Antibody measurement
IAV H1N1 and SARS-CoV ELISA
IAV hemagglutinin (HA)-specific and SARS-CoV spike-specific antibody were quantified by ELISA. 96 well flat-bottom plates were
coated with HA antigen (BEI Resources, Mannassas, VA, NR13691) or SARS S protein (BEI Resources NR722) (diluted in carbonate
buffer (0.32M Na2C03, 0.68M NaHCO3) to 1 mg/mL). Half-log serum dilutions (10
2 to 105.5) were prepared in wash buffer (0.033%
Tween-20 in PBS), added to coated plates, and incubated overnight in a humidified chamber at 4C. Plates were washed and incu-
bated with horseradish peroxidase (HRP)-conjugated secondary antibodies (Southern Biotech, Birmingham, AL, HRP conjugated
goat anti-mouse, IgM = 1020-05, IgG1 = 1070-05, IgG2a = 1080-05 pooled with IgG2c = 1079-05, IgG2b = 1090-05, IgG3 =
1100-05, Total IgG = 1030-05) for approximately 2 hours at 4C. IAV plates were washed and developed in the dark for 30 minutes
at room temperature with citrate substrate (.05M sodium citrate, 0.05M citric acid, 1mg/mL OPD, 0.216% hydrogen peroxide), then
stopped with sodium fluoride (0.1M) and read immediately at 450nm. SARS-CoV plates were washed and developed in the dark for
30 minutes with 3,30,5,50-tetramethylbenzidine (TMB) substrate (ThermoFisher Scientific, Waltham, MA, 34028), then stopped with
HCL (0.2M) and read immediately at 450nm. Background-subtracted ODmeasurements were set against dilution factors to calculate
area under the curve (AUC) values for each sample and isotype. AUC was determined to be the most inclusive measure to robustly
captured the dynamic range of antibody levels across our sample set, and performed better than other measurements such as half
maximal or lowest positive titer. To monitor consistency across assays, C57BL6/J immune sera as well as serum samples from CC-
F1s that were repeated across multiple cohorts were measured multiple times alongside different sets of experimental samples.
CHIKV ELISA
CHIKV-specific antibodies in mouse sera were measured using a virion-based ELISA as described (Hawman et al., 2016). CHIKV
strain 181/25 grown in serum-free media (VP-SFM) was concentrated, suspended in PBS, and was adsorbed to a 96-well Immulon
4HBX plate (1.25 3 108 particles/well). Serum samples were serially diluted and added to the plate. Bound antibody was detectedCell Reports 31, 107587, April 28, 2020 e4
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substrate (Sigma-Aldrich, St. Louis, MO). Endpoint titers were defined as the reciprocal of the last dilution to have an absorbance four
standard deviations greater than background. Blank wells receiving no serum were used to quantify background signal.
CHIKV Focus Reduction Neutralization Test (FRNT)
For FRNT assays, Vero cells were seeded in 96-well plates. Serum samples were heat-inactivated and serially diluted in DMEM/F12
medium with 2% FBS in 96-well plates. Approximately 100 focus-forming units (FFU) of virus stock (CHIKV strain SL15649) was
added to each well and the serum plus virus mixture was incubated for 1h at 37C. At the end of 1h, medium was removed from
Vero cells and serum sample plus virus mixture was added for 2 h at 37C. After 2 h, sample was removed and cells were overlaid
with 0.5%methylcellulose in MEM/5% FBS and incubated 18h at 37C. Cells were fixed with 1% PFA and probed with 500 ng/mL of
anti-CHIKV CHK-11 mAb (Pal et al., 2013) diluted in 1X PBS/0.1% saponin/0.1% bovine serum albumin (BSA) for 2h at room tem-
perature. After washing, cells were incubated with HRP-conjugated goat anti-mouse IgG for 1.5-2 h at room temperature. After
washing, CHIKV-positive foci were visualized with TrueBlue substrate and counted using a CTL Biospot analyzer and Biospot soft-
ware (Cellular Technology, Cleveland, OH). Percent infectivity was calculated compared to a virus only (no serum) control. The
FRNT50 value was defined as the reciprocal of the last dilution to exhibit 50% infectivity.
Expression analysis
Lung expression
Whole lungswere stored in RNAlater solution (QIAGEN, Hilden, Germany), kept at 4C for one day and subsequently stored at20C.
RNAwas isolated using QIAGENMidi Kit. RNA quality was controlled on a 2100 Bioanalyzer Instrument (Agilent, Santa Clara, CA). All
RNA samples had a RNA Integrity Number (RIN) ofR 9.5. 3 to 6 independent biological replicates were selected for each time point
for subsequent RNA sequencing. 500ng of total RNAwas used to prepare libraries for sequencing using the Lexogen SENSEmRNA-
seq library kit for Ion Torrent. Libraries amplified for 11 cycles as the final step of library preparation. Before sequencing, 1ul aliquots
of this material was pooled and sequenced on an Ion Torrent PGM 314 chip. Barcode quantification data from the PGMwere used to
balance the barcodes for final pooling before sequencing. Following this final pooling, the library pools were sized to a target size of
260bp on a Pippin Prep instrument using the 2%Pippin Agarose gel. The sized libraries were examined on an Agilent High Sensitivity
DNA chip, quantified using real-time PCR, and used to prepare spheres using a One-Touch 2 device. These spheres were then
sequenced on an Ion Torrent Proton sequencer with a P1 chip. The mean number of reads per sample was 24 million. Reads
were quality checked with package FastQC (Andrews, 2010), then trimmed using Trimgalore (Krueger, 2012). Trimmed reads
were mapped to mouse genome annotation mm10 (build 38.1) using STAR aligner (Dobin et al., 2016). Further analysis and visual-
ization of expression data was performed using the R software package. Mapped reads were feature counted (per gene) using
RsubRead (Liao et al., 2019). Raw counts from mouse genome and virus mapping were then combined and normalized using
DESeq2 (Love et al., 2014). After normalization, single extreme outlier points were razorized, log2 transformed, normalized expression
levels were then batch corrected using package sva (Leek, 2014). Extreme outlier samples were identified in principle component
analyses and removed. For each group, 3 to 4 replicates were retained. Log2 transformed, normalized and batch corrected expres-
sion levels were outputted for further use.
Blood expression
Analysis of expression data from blood was previously described (Kollmus et al., 2018). Briefly, blood was collected for RNA isolation
at multiple time points (days 3, 5, and 8) post-infection by retro-orbital bleed. RNAwas isolated, transcribed into cDNA, amplifiedwith
incorporation of cyanine 3-labeled CTP, and hybridized to a whole mouse genome microarray (Agilent 026655).
Candidate selection
All genetic elements under each QTL were first narrowed by choosing only those containing SNPs above the association testing
threshold. Association testing was performed via the assoc.map() function in DOQTL by imputing Sanger SNPs onto the CC genome
builds, and thresholds were set independently for each QTL. Candidate SNPs were then run through the Ensembl Variant Effect Pre-
dictor (McLaren et al., 2010) to determine the genetic classification of the affected gene as well as the predicted consequence of the
SNP itself. We selected variants in protein-coding genes only and then filtered to genes expressed in the lung, thymus, and/or spleen.
Coding variants were further considered if they were predicted to have a functional consequence on the protein product (e.g.,
missense versus synonymous variant). Non-coding variants were further considered if haplotype-specific expression differences
were observed in lung and/or blood. Genes with coding and/or non-coding variants that met these criteria were included in our final
list of candidate genes.
QUANTIFICATION AND STATISTICAL ANALYSIS
Heritability
To determine heritability for single time point measurements, we fit the following linear model:
Phenotype  CC F1+ εe5 Cell Reports 31, 107587, April 28, 2020
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OPEN ACCESSWe averaged intraclass correlation [(MSCC-F1 - MSε)/(MSCC-F1 + (N-1)MSε)] and coefficient of genetic determination [ (MSCC-F1 - MSε)/
(MSCC-F1 + (2N-1)MSε) ] values, using N = 3 as a representative value for group size across all CC-F1s.
Kinetics
Values for between-time point antibody measurements were determined by averaging raw AUC values for each CC-F1, then calcu-
lating ratios of between adjacent time points (day 10/day 7, day 15/day 10, day 45/day 15) for each isotype. Given only one calculated
measurement per time point per CC-F1, heritability and effect size could not be calculated for between-time point phenotypes.
Normalization
QTL mapping assumes that phenotypic data is normally distributed. Data for each isotype and time point combination varied in dis-
tribution, and therefore were normalized independently based on box-cox transformation values. Normalized single-time point mea-
surements were averaged per CC-F1 preceding QTL mapping.
Genetic mapping
Weconducted geneticmapping using the DOQTL (1.18.0) (Gatti et al., 2014) package in the R statistical environment (R Development
Core Team, 2008). Collaborative Cross genomes are best represented as a 36-state probability matrix (where at each marker, the
values indicate the likelihood that a mouse from that strain has a given homozygous (n = 8) or heterozygous (n = 28) diplotype).
We took the 36-state probability files from the CCMost Recent Common Ancestors (MRCAs) consensuses for each strain and simpli-
fied these to 8-state probabilities as previously described (Srivastava et al., 2017). For each CC-F1, we averaged the 8-state prob-
abilities of the two parent CC strains. This approach is the most accurate for F1 animals, as they will receive only one allele from each
parent CC strain. For genetic mapping in DOQTL, a multiple regression is run at each marker, running the phenotype of interest
against haplotype probabilities for each strain. LOD scores are calculated based on the improvement of fit in this model compared
to a null model considering only covariates and kinship. To determine significance, permutation tests were run in which phenotype
and genotype data are shuffled without replacement to generate a series of null LOD scores, of which the highest is archived. Based
on 1000 permutations, we determined null distributions. We calculated p value scores by empirical cumulative distribution function,
comparing the maximum LOD score for a QTL to the distribution of null permutations. QTL regions were determined using a 1.5LOD
drop interval.
Haplotype scoring
Once loci were identified, haplotype groups for each QTL were manually determined based on visualization of haplotype effect plots.
Additive haplotype scores for CC-F1s were computed by combining the haplotype scores for the dam and sire of the F1. CC-F1s
were dropped from analyses if either the dam or sire had heterozygosity or recombinations within the locus between founder hap-
lotypes with differing effect scores. In the case of Ari2, there was an insufficient number of representative crosses for one haplotype
effect group (only two F1s with an additive score of 0), and therefore this group was dropped from analyses.
Phenotypic variance
Effect sizes were computed by linear regression:
Phenotype  dam haplotype + sire haplotype+CC F1+ ε
We calculated [(Sum of Squaresdam + SSsire) / (SSdam + SSsire + SSCC-F1)]. QTL effect size was multiplied by trait heritability to deter-
mine the percentage of total phenotypic variation explained by the QTL.
Phenotypic correlations
Correlations between Ari loci and other phenotypes were calculated by running the following mixed effect linear models and
comparing goodness of fit between them with an ANOVA test to determine a p value. Haplotype ((0, 1) or (0, 1, 2)) was included
as a numeric variable representing the dosage of the allele associated with the high response.
Phenotype  CC F1+ εPhenotype  additive haplotype score + CC F1+ ε
To determine correlations with weight loss, Mx1 haplotype was included in both models:
Phenotype  additiveMx1 haplotype score + CC F1+ εPhenotype  additiveMx1 haplotype score + additive haplotype score+CC F1+ εCell Reports 31, 107587, April 28, 2020 e6
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haplotype scores. Since many animals did not reach maximal weight loss until after day 7, only animals from time points 10-45 were
included in these models.
Phenotype  additive haplotype score + CC F1+ εPhenotype  additiveMx1 haplotype + antibody measurement+CC F1+ εDIFFERENTIAL EXPRESSION ANALYSIS
Goodness of fit between the following mixed linear models was compared using an ANOVA test to determine IAV-specific (models
1&2) and haplotype-specific (models 2&3) expression.
1. Gene expression CC-F1 + ε
2. Gene expression day post-infection + CC-F1 + ε
3. Gene expression day post-infection + haplotype score + CC-F1 + εe7 Cell Reports 31, 107587, April 28, 2020
